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Thrombolytic Therapy in Acute Myocardial Infarction: An
Emergency Department Perspective

Bradford L. Walters, MD*

I

n the past several years there has been a revolution in the approach to acute myocardial infarction (MI) not unlike what
happened in the treatment of bacterial infections with the advent
of antibiotics. Physicians have been able to go from expectant
management of complications to attacking the root cause of MI
itselfi thrombosis of a coronary artery. In the past, patients with
chest pain were admitted to the coronary care unit (CCU) where
the ultimate diagnosis was made over a period oftimeas various
test results became available. Patients were watched for the development of complications such as arrhythmias or congestive
heart failure. The role of the emergency physician was to identify those patients who required admission and to keep them
alive until they could be transferred to the CCU. The majority of
the responsibility for treating the patient fell to the admitting
physician who, in most cases, was a cardiologist or intemist.

of a MI was still in question in that era. While coronary artery
thrombosis was postulated as the inciting event of an acute MI
by Herrick (2) in 1912, not untti 1980 did DeWood et al (3) demonstrate angiographically that 90% of patients within 4 hours of
the onset of symptoms had obstmction of the infarct artery by a
thrombus. In light of such findings, thrombolytic therapy was
reconsidered with greater intensity. Additionally, DeWood et al
(3) demonstrated the safety of coronary angiography in the early
period of an acute MI, establishing the basis for assessing the effects of thrombolytic therapy in subsequent studies.
In the history of medicine no class of agent has been studied
with the same intensity as the thrombolytic agents. Nor have so
many patients been enrolled in such a short time in trials that are
routinely intemational in scope. To provide optimal treatment,
the emergency physician must be aware of the recommendaThe treatment of acute MI changed radically with the develtions for thrombolysis, the studies that demonstrate specific apopment of thrombolytic therapy in the 1980s, and the entire applications, and the trials that have modified those applications.
proach to acute MI continues to be revolutionized. With the abilThe initial patients to receive thrombolytic therapy were
ity to dissolve clots within the coronary artery came a need to
those in whom the risk of complications was low. Patients were
initiate this treatment as rapidly as possible. Thus, the emerexcluded if they had hypertension, a history of stroke, or were
gency physician has become a central figure for most patients
elderly. Typical inclusion and exclusion criteria for those initial
with an acute MI who present to the emergency department.
trials are shown in Table 1; such criteria became the standard inTime constraints made il impractical to wait for the cardiologist
dications and contraindications for thrombolysis for many hosor intemist to come in to treat the patient. Protocols were develpital protocols.
oped that allowed the emergency physician to assess the indicaIn many cases the exclusion criteria are subjective and impretions and contraindications of thrombolytic therapy, to initiate cise. The exclusion of patients with a history of stroke is a good
treatment with such agents, and to begin treatment with adjuncexample. Is the risk of thrombolysis different for the patient who
tive therapies without first consulttng the admitting physician.
experienced a stroke 15 years previously compared to the one
It placed greater responsibilities upon the emergency physician
who had a stroke three months prior to the acute MI? How long
as he or she was required to balance a myriad of factors and poafter "major" surgery is it safe to administer a thrombolytic
tential therapies that were not required in the prethrombolytic
agent? Is there a difference in risk between a vigorous 80-yearera. The various indications, absolute and relative contraindicaold and a chronically ill 60-year-old patient? The treating physitions, risk factors, interpretation of ECGs, and which adjunctive cian must keep in mind that many of the exclusion and inclusion
agents to use all must be addressed by the emergency physician
criteria were developed from studies whose primary goal was to
in a short time. This article examines many of the issues conselect patients who had the lowest risk of complications. These
fronting the emergency physician using thrombolytic agents to
are not necessarily the kinds of patients who present with an
treat a patient with an acute MI.
acute MI to the average emergency department. A major diffi-

Rationale for the Use of Thrombolytic Therapy
The use of thrombolyfic agents for acute MI is not new. Initial
work with streptokinase (SK) was reported in the late 1940s (1).
However, whether coronary thrombosis was the cause or result
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culty of providing thrombolytic therapy is to select patients
likely to benefit from such treatment and to exclude those in
whom the risk of a complication is excessive. The emergency
physician must be aware of the "gray areas" because many patients do not fall neatly into inclusion and exclusion categories.
Knowledge of these areas allows the physician to maximize the
use ofthis powerful treatment for acute Ml.

Intracoronary Versus Intravenous
Thrombolytic Therapy
Initial studies of thrombolytic therapy involved the intravenous administration of SK (4). The first clinical trials did not
show significant reductions in the most crucial parameter, mortalily (5,6). These initial studies wereflawedby use of low doses
and late administration of SK. Subsequently, intracoronary administration of SK was demonstrated to be feasible and highly
effective in reestablishing perfusion in a coronary artery occluded by thrombus if administered early after the onset of
symptoms (7-9). In the Westem Washington trial, a substantial
reduction of in-hospital mortality was demonstrated using intracoronary SK (10). Patients treated early in the time course of
symptoms (average of 4.6 hours) showed a 67% reduction in
mortality (10). Other trials showed similar reductions in mortality using intracoronary thrombolytic agents (11-13). The importance of time is one of the most consistent findings; every study
has shown that the sooner a patient is treated, the better the results. Despite the benefits of intracoronary thrombolytic agents,
their administration presents formidable obstacles. First, only a
small number of hospitals have the angiography facilities (19%
as of 1986) (14). Second, substantial delays are incurred because
of the time needed to call in personnel to the angiography suite,
particularly during off hours. Finally, the intracoronary infusion
of a thrombolytic is expensive.
The issue became moot when trials using the intravenous
route demonstrated a reduction in mortality equivalent to that
achieved with intracoronary administration. Furthermore, intravenous administration of a thrombolytic agent could be
achieved not only with greater ease and speed but also within the
emergency department. The first two megatrials using intravenous SK (Gruppo Italiano per lo Studio della Streptochinasi
nell'Infarto Miocardico [GISSl-1] and the Intemational Study
of Intravenous Streptokinase [ISIS-2]) showed a mortality reduction equal to that in the intracoronary studies (15,16). Results of smaller trials were similar but the mortality reductions
were not always statistically significant (17-19). Mortality reduction in these studies ranged from 11% to 66%. Tissue-plasminogen activator (t-PA) was shown to achieve patency rates
equivalent to that achieved with intracoronary agents when administered up to 6 to 8 hours after the onset of symptoms (2023) (Fig 1). Virtually all therapy is now given intravenously and
treatment with these agents moved from the angiography suite
to the emergency department.
Despite the ease with which intravenous thrombolytic agenls
can be given, a sizable proportion of Ml patients are ineligible
forthis therapy using the inclusion criteria of the major trials. In
many trials, patients who were at any risk for a complication
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Table 1
Inclusion and Exclusion Criteria
for Thrombolytic Therapy
Inclusion Criteria:
1, ECG changes consistent with acute ischemia which do not reverse with nitroglycerin administration (1 to 2 mm ST segment elevation in two
contiguous leads)
2, Age < 75 years
3, Duration of chest pain < 6 hours from onset to presentation
4, Ability to understand therisksinvolved in thrombolysis
Exclusion Criteria:
1, Excessive time from the onset of pain to presentation for medical care (i,e,,
6 to 12 hours unless there is persistent pain and/or ST segment elevation on ECG)
2, Age > 75 years
3, Uncontrolled hypertension (> 180/110 mm Hg)
4, History of cerebrovascular accident, stroke, transient ischemia attack,
arteriovenous malformation, or brain tumor at present or at any time in the past
5, Prolonged cardiopulmonary resuscitation
6, History of bleeding diathesis, clotting abnormality, or on anticoagulants
7, Recent puncture of a noncompressible blood vessel (i,e,, subclavian vein,
bladder fulguration. or polyp removal)
8, Recent trauma or major surgery; advanced or terminal illness
9, Pregnancy or women of childbearing potential

% Infarct Artery Patency
100

% Coronary Patency
Symptom Onset to Therapy (Hours)
10-2

CZ] 2-3

C 3 3-4

4-5

C 3 5-6

C H 6-8

Fig 1—Vessel patency for t-PA. (Adapted ft-om Topol EJ. Advances In thrombolytic therapy for acule myocardial infarction.
J Clin Pharmacol 1987;27:735-45.)

were excluded. Moreover, the requirement to treat patients in
the early stages of a Ml eliminated an additional number of eligible patients. In the Thrombolysis in Myocardial Infarction
(TIMI) trials, only 9% to 14% of patients with acute Mls met the
inclusion criteria (24,25). Even liberalizing the inclusion criteria
(e.g., by increasing the time frame of symptoms up to 6 hours)
increases the percentage of patients eligible for treatment to only
25% (26-28). The major reason for excluding patients was that
the duration of symptoms was too long; additional factors were
age (over 75 years) and a nondiagnostic ECG (29). The AngloScandinavian Study of Early Thrombolysis (ASSET) did nol
use any ECG criteria, and the GISSl trial included patients up
to 12 hours from symptom onset. This increased the eligibility
rates of patients presenting for treatment to 38% and 37%, re-
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spectively (15,30). It is important to realize that there is a high
mortality rate in those patients who were excluded from these
trials. In the TIMl-llb trial, tbe in-hospital mortality for participating patients was 2.5% whereas mortality was 18% for those
who were excluded because of some contraindication (25).
These excluded patients represent a population that might derive significant benefit from thrombolysis (15,30,31). Despite
the huge number of patients who have participated in various trials, the guidelines still are such that a majority of patients are excluded by some contraindication. If thrombolysis is to have a
more substantial impact on the mortality of acute MI, issues of
patient eligibility must be explored in the hope of including
more patients.
The issue of determining a patient's eligibility for treatment
has become a major responsibility of the emergency physician.
Cooperation with admitting physicians (i.e., cardiologists and
intemists) has provided emergency physicians the freedom to
make the initial decisions regarding thrombolytic therapy prior
to contacting the admitting physician. While this allows for
faster initiation of therapy, it has thrown greater responsibility
on the emergency physician. The various criteria for thrombolytic therapy are in a state of flux. An intimate knowledge of
this area will allow the emergency physician to provide this
therapy with the least risk for subsequent complications.

Criteria for Thrombolytic Therapy
ECG criteria
Most trials of thrombolytic therapy required strict ECG evidence of infarction as a key inclusion criterion. Such acute
changes assure a greater probability that the patient will actually
be having a MI at the time of treatment. Typical ECG criteria are
1 to 2 mm of ST segment elevation in two contiguous leads.
Some trials included the caveat that the ST segment elevation
must persist after nitroglycerin administration, eliminating coronary artery spasm as an etiology ofthe acute MI. This ECG criterion has been relatively standard as an absolute indication for
thrombolytic therapy. However, not all trials used ECG changes
to screen patients for inclusion in the study. Both the ASSET
and ISIS-2 trials based inclusion of patients purely on clinical
and historical findings without requiring acute ECG changes. In
these two trials, patients with chest pain and normal ECGs had
a mortality rate that was low and minimal benefit was derived
from thrombolytic treatment (30,32). In the GISSl-1 and ISIS-2
trials, patients with chest pain and only ST segment depression
on their ECG also derived little benefit from treatment with
tbrombolyfics. Contrary to the belief that patients with only depressed ST segments represent a low-risk group, this group
proved to have a high mortality rate in both trials (16.3% and
20.5%, respectively) (15,29,32). Presentiy, acutely elevated ST
segments is an absolute requirement before a patient can be considered for thrombolytic therapy.
The controversy of infarction location has also been an issue
of thrombolytic therapy and ECG inclusion criteria. A number
of studies have demonstrated that patients with inferior wall infarctions have a relatively low mortality rate. Pooled data from
approximately 12,000 patients with inferior Mls treated with
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thrombolytic agents disclose a reduction in mortality from 8.7%
in the control group to 6.8% in the treated group (29). While not
as great a mortality reduction as that seen in anterior Mls, it is
still significant. Exclusion based on location of the infarct does
not seem justified.
Another area that can challenge the emergency physician relafive to ECG interpretation involves those patients who have a
left bundle branch block (LBBB). Interpretation ofthe ECG for
ischemic changes is difficult in the presence of a LBBB. Results
in this group of patients from the GISSl-1 trial showed litfie
mortality difference between control and treated groups (8.6%
versus 8.0%, respecfively) (15). In contrast, in the ISIS-2 trial,
patients with a LBBB had a mortality rate of 27.7% in the control group which decreased to 14% in the SK plus aspirin treatment group (32). In the absence of other contraindicafions, patients with chest pain consistent with MI and a LBBB should be
considered for thrombolytic treatment even without acute ECG
changes. However, patients who have chest pain but whose
ECG is normal or shows only ST segment depression should be
observed with serial ECGs and/or taken for emergency angiography.
Serum enzyme changes
Thetimeconstraints involved in treating patients with thrombolytic agents are such that the emergency physician cannot
wait for most laboratory tests to be performed. However, those
patients who do not qualify for treatment based on ECG criteria
are frequentiy observed for a short time in the hope of seeing
some change that will allow the diagnosis of acute MI. In a pilot study of patients with chest pain and nondiagnostic ECGs,
serial creatine phosphokinase MB band (CPK-MB) assays were
drawn to determine whether the pattem ofrisingenzyme levels
correlated with having an acute MI. While an isolated total CPK
or even CPK-MB assay may yield no significant information,
repeated studies over a short time may reveal a trend that is sensitive and specific for infarction. In the pilot study arisingtrend
in CPK-MB was strongly correlated in those patients who were
having an acute MI. In patients who have chest pain and nondiagnostic ECGs, serial CPK-MB testing may rapidly identify
those who could benefit from thrombolysis (33).
Time to treatment
The time span between the onset of symptoms and the inifiation of treatment with a thrombolytic agent has been a powerful
predictor of success. In the first megatrial, GISSl-1, littie benefit
was found in patients first treated beyond 6 hours of the onset of
symptoms (15). This observafion correlates with the finding in
animals that irreversible myocardial necrosis occurs within 6
hours after occlusion of a coronary artery (34). This 6-hour
period has been accepted as the fime limit in which patients
must be treated with thrombolytic agents. However, thetimeof
symptom duration can be difficult to determine accurately because few patients know precisely when their pain began. Minor
chest pains may precede the pain for which the patient then
seeks medical care. Pafients may not note thefimetheir pain began or may be poor historians. Accordingly, initiating or withholding thrombolytic therapy based on rigid time guidelines is
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fraught with inaccuracy. The issue becomes even more confused by results of studies in which patients were treated late.
Pafients who survive the first 6 hours after a MI are sfill at high
risk of dying and may benefit from thrombolysis (15,32,35).
Combined data from several studies in which pafients were
treated up to 24 hours after the onset of symptoms show a significant reducfion in mortality rates using intravenous SK (Fig 2).
In the 6-to 12-hourttme frame, mortality was 13% in the control
group compared to 11.6% in the treated cohort. When 12 to 24
hours elapsed between onset of symptoms and treatment, mortality was 11.8% in the control group versus 8.7% in the group
given thrombolyfic agents (29). These results were achieved despite the fact that SK is not particularly effecfive in lysing clots
late in the course of coronary artery occlusion (36).
Thus, the decision whether to begin thrombolytic therapy is
difficult when the time of onset of symptoms is uncertain. Emergency physicians have tumed to other factors to help make this
crifical decision in those patients who present late. Ongoing
chest pain, continued presence of acute changes on ECG, and
lack of other contraindications to thrombolysis have been used
to "justify" the use of thrombolytic agents in such patients.
A second important time factor that can impact patient outcome is that required to initiate thrombolytic therapy. Long delays in the emergency department can influence the success of
thrombolysis. The TIMI-II trial patients who presented to the
Hennepin County Medical Center in Milwaukee, WI, experienced substantial delays in the emergency department before
treatment was initiated. The average time to complete required
studies, interpret the results, place the intravenous lines, and obtain the thrombolytic agent from the pharmacy was approximately 90 minutes. It took even longer if the patient bypassed
the emergency department and went directiy to the CCU (37).
Expediting this process is an essential responsibility of the
emergency physician. Many departments have established protocols in which patients suspected of myocardial ischemia are
treated with the same team approach as trauma victims.
Bleeding risk
Some of the complications of thrombolytic therapy are bothersome and not life-threatening. They can usually be treated
without interfering with the infusion of the thrombolytic agent.
For example, the allergic reaction which can occur with SK will
generally respond promptly to treatment with antihistamines
and steroids. In most cases the infusion of SK need not be halted
or may be stopped for a short time.
Bleeding that occurs subsequent to thrombolytic therapy is
the most serious and a potentially fatal complication. Sometimes the bleeding is minor, such as oozing from a venipuncture
or intravenous site. However, major bleeding can occur in the
retroperitoneal space or intracranially causing a stroke. It is difficult to predict which patient may suffer a serious bleeding
complication. Prolonged infusions of a thrombolytic agent and
older age will increase the risk for bleeding (38,39). Other factors that increase the risk of hemorrhage are poorly understood,
such as the excess bleeding found in hypertensive, thin, elderly
women (40) whether or not they undergo an invasive procedure
such as angiography (29).
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30.0%

20,0%

10,0%
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Elderly
Trealed

Time 6-24 Hrs,

tiXlJ Control

Fig 2—MortaUty rates for inferior MI, the elderly, and symptom
duration. (Adapted from Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for acute myocardial Infarction:
Concepts and controversies. J Am Coll Cai-dlol 1990;16:22332.)

The most feared bleeding complication and that most frequentiy associated with a morbid outcome is intracranial bleeding (ICB). In a study of 154 cases of spontaneous ICB (not associated with thrombolytic therapy), 54% of the patients were hypertensive on presentation, 45% gave a history of hypertension,
and 46% were elderly. A total of 27% had a prior cerebral event
such as a stroke or intracranial tumor. However, 41 % of the patients who suffered ICB had no obvious risk factor for ICB (41).
Patients who are elderly or hypertensive or have a history of
stroke or intracranial tumor are considered al high risk for ICB
and are excluded from thrombolytic protocols. In the Thrombolysis and Angioplasty in Myocardial Infarction study, 0.7% of
the patients suffered ICB. The investigators could identify at
least one risk factor in each of these patients. However, 80% of
patients who did not have ICB also had one such "risk" factor. In
fact, the authors were unable to identify patients with a high potential for ICB based on age, aspirin use, hypertension, or prior
cerebrovascular accident (42). Thus, while hypertension and advanced age do increase the risk for ICB in patients undergoing
thrombolysis, the event is difficult to predict in a specific patient.
All thrombolytic agents seem to be associated with a similar
rate of ICB (Table 2). SK, t-PA, and anisoylated plasminogen
streptokinase activator complex (APSAC) given intravenously
have a rate of ICB of 0.4% to 0.5% (39,43,44). This complication rate was found with a t-PA dose of 100 mg. In the TlMI-llb
study, a dosage of 150 mg was associated with a rate of ICB of
1.9%. In view of this result, 100 mg of t-PA is the most commonly used dose (39). Newer regimens have been proposed
using weight-dosing and front-loading protocols in addition to
combinations with other agents. Inilial studies have demonstrated no increase in ICB, raising the possibility that t-PA therapy can be safely administered in a regimen that may maximize
coronary artery patency (45-48).
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Table 2
Comparison of the Thrombolytic Agents*
SK
Dose
Patency
Time-dependent
Hypotension
Half-life
Fibrinogen
depletion
ICB
Allergic reactions
Repeat dosing
Cost

t-PA

APSAC

1,5 million units
50%
+++, < 30% after
4 hours
Severe in < 5%
of patients
20 minutes

100mgx3hrs
70% to 75%
Little
demonstrated
Rare

Like SK

5 minutes

90 minutes

++++
< 0.5%
Yes
No
$264

+
< 0.5%
No
Yes
S2.200

< 0.5%
Yes
No
$2,375

30 units
50% to 55%
Unknown

•Adapted from Topol EJ, Advances in thrombolytic therapy for acute myocardial infarcdon, J Clin Pharmacol 1987:27:735-45,
SK = streptokinase. t-PA = lissue-plasminogen activator, APSAC == anisoylated plasminogen streptokinase acdvalor complex, ICB = intracranial bleeding.

Hypertension
Hypertension is an important consideration in patients undergoing thrombolytic therapy because of the increased risk for
ICB. Hospital protocols for the use of thrombolytic agents have
absolute and relative contraindications based on blood pressure.
However, it is not clear what actually constitutes an unacceptable level of hypertension (Table I). The important question of
whether hypertensive patients whose blood pressure is controlled in the emergency department can be treated safely with
thrombolytic agents has not been studied adequately.
The causes of hypertension are multifactorial with anxiety
and pain playing a significant role. Hypertension due to pain
and/or anxiety often cannot be distinguished readily from chronic hypertension. However, such situational causes of hypertension should respond to medications that control pain and anxiety
(e.g., nitrates and narcotics). Persistent hypertension may require the use of antihypertensive agents such as nifedipine, parenteral nitroglycerin, or nitropmsside. Careful titration of antihypertensive therapy is important because inducing hypotension could worsen myocardial ischemia. When acceptable blood
pressure levels are achieved in patients, many emergency physicians will commence thrombolytic therapy. Justificafion for this
policy is found in the ISIS-2 study in which 1,141 patients
whose initial systolic blood pressure was over 175 mm Hg were
entered into the study. The treatment group mortality was less
than that of the control group, 5.7% versus 8.7%, respectively
(32). Thus, in hypertensive patients without other contraindications to thrombolysis, whose blood pressure can be controlled
adequately in the emergency department, thrombolytic therapy
offers improved mortality.
Age
Most eariy trials of thrombolytic agents restricted their use to
younger patients. The age of 75 years was the usual upper limit
for treated patients. Data regarding the risk of bleeding, particulariy ICB, seemed to support such caution. However, this el-
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deriy group frequently presents to the emergency department
with acute MI. People older than 65 years comprise the fastest
growing population group in the United States. In 1987 this age
group comprised 12% of the population and is expected to rise
to 20% by the year 2030. The fastest growing segment of this
elderly group, those over 85 years old, represents a pool of patients in whom thrombolysis can offer substantial benefits (49).
The mortality rate for acute Ml and the incidence of associated
complications such as congestive heart failure and left ventricular failure are higher in the older age groups (50-55). In several
of the trials that included patients older than 75 years, higher
mortality and increased incidence of hemorrhagic complications were seen in the older patients (56,57). However, not ati
studies report more frequent complications in elderly patients.
In GISSl-1, the group of 592 patients over age 70 had no greater
incidence of bleeding complications relative to younger patients
(15). Whatever the risk of thrombolysis, the elderly age group
showed significant mortality benefit from treatment (Fig 2). In
the ISIS-2 trial, patients older than 70 years in the control group
had the highest mortality rates of the entire study (21.6% to
23.8%). This same group obtained a substantial benefit from
treatment with reductions in mortality ranging from 15.7% to
33.6% (32). Pooled data from five large trials (Intravenous
Streptokinase in Acute Myocardial Infarction study, GlSSI-1,
ISIS-2, ASSET, and the APSAC Intervention Mortality Study)
revealed that the mortality rate for elderiy patients was 22.1 % in
the control groups which was reduced to 17.9% in the treated
groups (P < 0.0001) (Fig 2). The conclusion that strict chronologic age should not be used as an absolute contraindication to
thrombolytic therapy seems justified.

Recent Megatrials
Within the past year some of the concepts and controversies
regarding thrombolytic therapy have been addressed in two ambitious trials. The GISSl-2 and ISIS-3 megatrials attempted to
address the controversy over which agent is better, SK or t-PA.
Both trials were large and included the use of aspirin and heparin as adjunctive agents. In addition, both trials liberalized inclusion criteria in order to enroll older patients and those with
longertimeintervals from the onset of symptoms. In the ISIS-3
trial, one arm of the protocol looked at atypical presentations including patients who did not have acute ECG changes.
Before the results of these trials can be evaluated, it is important to note the mortality rates established by preceding trials.
Pooled data from 25 major trials show a mortality rate of 11.8%
in the control group (n = 18,679), 9.4% in the SK treatment
group (n = 16,824), and 5.6% in the t-PA treatment group (n =
8,501) (58).
The GISSI-2/Intemational study consisted of two trials which
followed identical protocols; the GISSI-2 trial and the Intemational t-PA/SK mortality trial. The Intemational trial included
participants from 13 countries while GlSSI-2 was confined primarily to Italy. Because the thrombolytic protocols were the
same for both, the data have been combined for analysis.
The GlSSI-2/International study enrolled 20,891 patients
randomized to receive intravenous t-PA (100 mg) or SK (1.5
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million units). A second randomization divided patients into the
heparin and placebo-heparin groups. Patients in the heparin
group received 12,500 untts subcutaneously starting 12 hours
after administration of the thrombolytic agent. All patients received aspirin and those who qualified were given beta-blockers. No statistical difference in mortality was seen between SK
or t-PA (8.5% and 8.9%, respectively). There was also no
mortality difference between the heparin and placebo-heparin
groups. Both agents were associated with an equal number of
bleeding complications and strokes (59-61).
The lSIS-3 trial compared SK, APSAC (antistreplase), and tPA (duteplase) in a randomized protocol. This study included
46,092 patients from 20 countries who were divided into the
"certain" and "uncertain" groups in terms of the indications for
thrombolysis. The "certain" group presented within 6 hours
with typical chest pain accompanied by an ECG showing acute
changes. These patients were randomized first to receive one of
the three thrombolytic agents and then into the heparin or placebo-heparin group. The heparin was given as in GISSI-2,
12,500 units subcutaneously, but was started 4 hours after the
thrombolytic agent. The "uncertain" group included patients
with typical chest pain who presented beyond 6 hours after the
onset of symptoms and/or did not have acute ECG findings. Patients in this group were first randomized into a no thrombolytic/
aspirin only/placebo group and a thrombolytic group. The
thrombolytic group was then randomized to receive one of the
three agents as done in the "certain" group. The primary endpoint of this trial was mortality at five weeks.
The results of lSIS-3 have yet to be published but some of the
findings have been presented at conferences in the United States
(Table 3). The mortality rates were not statistically different
among the three thrombolytic agents with or without heparin.
Available subgroup analysis revealed no mortality difference
among the three agents in patients presenting within 6 hours of
symptoms and who had ST segment elevation on ECG (the "certain" group). Except for allergic reactions (more frequent with
SK and APSAC as expected), the side effects were similar for
all agents. Complications were infrequent, demonstrating the
safety of thrombolysis even when patients outside tradifional
parameters are included. One unexpected finding was the higher
rate of ICB for t-PA compared to SK and APSAC (Table 3).
However, only two-thirds of the ICB events were confirmed by
computed tomography or at autopsy. The remainder were diagnosed by clinical findings subject to interpretafion by the treating physician. Data from numerous other studies have shown
virtually identical ICB rates for all three agents, approximately
0.4% (30,32,36,39).
Controversy continues over the conclusions of the GISSl-2
and ISIS-3 trials, particularly over the dose, subcutaneous route
of administration, and delayed administration of heparin. Moreover, the anticoagulation effect of heparin was not monitored in
either trial as is typically done in the United States. Therefore,
the results of these two trials still do not indicate the "best"
thrombolytic agent in the judgment of many practitioners. In the
United States, patients are usually given 5,000 units of heparin
intravenously immediately after the thrombolytic agent has
been administered. The bolus is followed by an infusion of
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Table 3
ISIS-3 Results*

Mortality:
Treated patients
Mortality (0-35 days)
Mortality in patients
within 6 hours + ST
segment elevation
Severe Side Effects:
Allergic reaction
causing shock
Hypotension requiring
medication
Major bleeding (transfused)
Reinfarction
Strokes, In-hospital:
Probable ICBt
Other stroke
Total strokes

t-PA

SK

APSAC

13,290
10.3%
9.6%

13,295
10,5%
9,9%

13,328
10,6%
10,1%

0.1%

0.3%

0,6%

4,3%

6.8%

7,2%

0,9%
3,1%

0,9%
3,6%

1,0%
3,8%

0,7%
0,8%
1,5%

0,3%
0,8%
1,1%

0,6%
0,9%
1,5%

•Personal communication, James F, Buchanan, PharmD, Augu,sl 19, 1991,
tProbable strokes were clinically diagnosed, two-thirds by computed tomography,
l-PA = lissue-plasminogen activator, SK = streptokinase, APSAC = anisoylated plasminogen streptokinase activator complex, ICB = intracranial bleeding.

1,000 U/hr adjusted by the coagulation status which is monitored frequently to maintain the patient in a therapeutic range.
How the differences in heparin use affected the mortality and
complicafions in the GISSI-2 and ISIS-3 trials is uncertain.
However, in two studies of the effect of heparin and l-PA on coronary artery patency, results were significantiy better when intravenous heparin was given immediately after the t-PA infusion (62,63).
Two notable differences between SK and t-PA are I) the short
half-life of t-PA (approximately 5 minutes compared to 20 minutes for SK), and 2) t-PA produces far less fibrin split products.
The longer half-life of SK, along with the greater quantity of fibrin split products, produces a more sustained systemic lytic
state than that produced by t-PA (Table 2). Therefore, therapy
with t-PA might prove to be more sensifive to the anticoagulant
effect of immediate intravenous heparin in order to maintain a
longer lytic state. Delayed administration of subcutaneous heparin may have influenced the results of t-PA more than that of SK
in the GISSI-2 and lSlS-3 trials. Pooled data from a number of
studies confirm that mortality is lower in patients who receive
intravenous heparin than in those who do not. In 34,581 patients
from five different trials (GISSl-1 and -2, lSIS-2, the HeparinAspirin Reperfusion Trial (HART), and the Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto
[SCATI] trial) who received either t-PA or SK without heparin,
the combined mortality rate was 9.3% (15,32,59,60,62,64). The
9,298 patients from 15 different trials (ASSET, the European
Cooperative Study Group trials I-V, HART, ISIS-2, National
Heart Foundation of Australia Coronary Thrombolysis Group,
New Zealand I-ll, SCATI, TIMI-II pilot-IIa-IIb) who received
intravenous heparin after either SK or t-PA had a pooled mortality rate of only 5.5% (30,32,39,62,64-74). Along the same lines.
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a summary of the ISIS-2 data by Topol (75) revealed the following mortality rates; SK 4- aspirin = 9.6%; SK 4- aspirin + subcutaneous heparin = 7.6%; SK 4- aspirin 4- intravenous heparin =
6.4%. The group receiving intravenous heparin again had the
lowest mortality rate (75).

Adjunctive Agents and Thrombolytic Therapy
Aspirin
In various studies, a number of adjunctive agents combined
with thrombolytic therapy have been found to be extremely beneficial. Several enhance the lytic state created by the thrombolytic agent and others have been found to have mortality benefits. Generally, the emergency physician inifiates the administration of these adjunctive agents.
The simplest to use and one of the most effective adjunctive
agents is aspirin. Its antiplatelet effect reduces the reinfarction
rate and augments the improvement in mortality achieved by
thrombolysis. In the lSIS-2 trial, the beneficial effect of aspirin
was equal to that of intravenous SK alone in terms of reduced
mortality. There was further reduction in mortality when aspirin
was combined with SK (32). Since that study, aspirin has been a
part of virtually all trials of thrombolytic agents including those
reporting the lowest mortality rates yet (39,70). In a study of 100
patients with anterior acute MI treated with a thrombolytic and
heparin, the incidence of reinfarction was significantiy lower in
the group receiving aspirin (76).
The amount of aspirin administered has varied in different trials. Doses between 80 to 325 mg/day have been used and most
protocols call for the first dose to be given in the emergency department. It is recommended that the first dose be chewed to
promote faster absorption. The American College of Cardiology/American Heart Association currently suggests a dose of
160 mg/day beginning immediately in patients undergoing
thrombolysis (77).
Heparin
Heparin is the second adjunctive agent to consider. Its use,
benefits, risks, and routes of administration are controversial.
Current pracfice in the United States is lo administer heparin intravenously with or just after the thrombolytic agent. Frequent
monitoring of the anticoagulation status is important to assure
that therapeutic levels are achieved rapidly. The goal of heparin
therapy is to prevent reocclusion of the coronary artery once
thrombolysis has been successful. The optimal regimen has yet
to be determined. The TIMI-1 trial proposed a 5,000 U bolus of
heparin given immediately after infusion of the thrombolytic
agent. Thereafter, an infusion of 1,000 U/hr should be adjusled
to maintain an activated partial thromboplastin time 1.5 to 2.0
times greater than control. This regimen has become standard in
most thrombolytic protocols employing intravenous heparin
(36). However, other regimens of heparin administration have
been advocated, notably in the GISSI-2 and ISIS-3 trials in
which heparin was given subcutaneously some time after the
thrombolytic agent had been infused. Concems over this delay
in heparin administration and the lack of anticoagulation monitoring have been discussed. The HART trial (62) and Bleich et al
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(63) suggest a synergistic effect between heparin and t-PA.
There are also data to support the concept that heparin is an important adjunctive agent with SK (75). In the SCATI trial, patients receiving SK were given a bolus of intravenous heparin
followed by subcutaneous heparin. The heparin group had significantly lower mortality (4.6%) compared to the control nonheparin group (8.8%) (64). Subcutaneous, unmonitored heparin
has not been used extensively in the United States and intravenous heparin has been widely accepted.
Percutaneous transluminal coronary angioplasty
One adjunctive treatment to thrombolysis which seemed
promising initially has been found not only to be ineffective in
lowering mortality but actually to increase complications. It
seems logical that to open up an area of stenosis caused by an
atherosclerotic plaque in a coronary artery would help prevent
reocclusion and subsequent ischemia. Coronary thrombosis
commonly occurs in the narrowed artery lumen where the
plaque also acts as a nidus of thrombosis. In a number of studies
percutaneous transluminal coronary angioplasty (PTCA) was
performed soon after thrombolysis, aiming to open up any
stenotic areas in the infarct artery. In the TIMI-Ila and -lib trials,
patients who underwent early PTCA had no lower mortality
than those treated conservatively with delayed angiography and
highly selective angioplasty. In addition, complications such as
bleeding requiring transfusion were more common in the early
PTCA group (39,68,74,78,79). Early angiography with PTCA
offers no mortality benefii and increases complications. The
need for angioplasty in an otherwise stable patient is low.
Beta-blockers
Although not directiy synergistic with thrombolytic agenls,
beta-blockers are considered to be important adjunctive agents
in patients with acute MI. Beta-adrenergic blockade reduces the
oxygen demand of the myocardium and has been found to improve the prognosis of patients in studies not involving thrombolytics (80). In the TIMI-IIb trial, metoprolol was given intravenously to patients who had no contraindications to betablockade (Table 4). The dose was 15 mg given intravenously (in
three 5 mg doses over 15 minutes) followed by oral metoprolol.
This use of beta-blockers reduced the incidence of recurrent,
nonfatal infarction and lowered mortality in comparison to
those given oral beta-blockers starting six days after thrombolysis (39). In the absence of any contraindications, patients undergoing thrombolysis should receive beta-blockers in an effort to
reduce mortality further.

Choice of Thrombolytic Agent
and Dosing Regimen
No aspect of thrombolytic therapy engenders as much controversy as does the choice of agent. Currentiy there are three drugs
in clinical use: SK, t-PA, and APSAC (Table 2). Urokinase has
been used both alone and in combination with other thrombolytics but is not commonly used clinically. Each thrombolytic
agent has a slightly different physiologic profile which the
emergency physician must keep in mind.
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Table 4
Contraindications for Beta-Blockers
in Acute Myocardial Infarction*
Absolute Contraindications:
• Heart rate < 60 beats/min
• Systolic blood pressure < 100 mm Hg
• Moderate to severe left ventricular failure
• Peripheral hypoperfusion
• AV blocks: PR interval > 0,22 sec. type I-Il AV block, complete heart block
• Severe COPD
Relative Contraindications:
• History of asthma
• Currently taking beta-blockers
• Currently taking calcium channel blockers
• Severe peripheral vascular disease
• Brittle insulin-dependent diabetes mellitus
*Adapted from Gunnar RM, Bourdillon PDV, Dixon DW, et al, ACC/AHA guidelines
for the early managemeni of patients with acute myocardial infarction. Circulation 1990;
82:664-707,
AV = arterioventricular, COPD = chronic obstructive pulmonary disease.

SK is the agent which has been in use the longest and with
which we have the greatest clinical and experimental experience. Derived from bacteria, it is a foreign protein and has allergic and anfigenic potenlial. In studies of arterial patency, SK had
a significantiy lower rate compared to t-PA (36). However, data
from the GlSSI-2 and ISIS-3 trials have not shown that higher
patency rates influence mortality as both SK and t-PA were similar in that respect (59,60). A nonclol-specific agent, SK acts on
plasminogen throughout the body. Levels of fibrinogen fall precipitously and levels of fibrin split products rise (Table 2). These
effects, along with the relatively long half-life of SK, prolong a
sustained generalized lytic state. SK seems to produce a modestly higher incidence of hypotension and serious bleeding requiring transfusion compared to t-PA (59,60). The incidence of
allergic reactions is low and generally responds to treatment
with antihistamines and/or steroids. Many physicians no longer
pretreat patients for allergy as was once advocated with SK.
However, the antigenic potential of SK is significant in that patients develop antibodies to SK and the agent cannot be readministered at a later date (Table 2). In virtually all trials the current dose of SK is 1.5 million units infused over 60 minutes.
t-PA is a dmg derived from a recombinant DNA process. It is
clot-specific in that its thrombolytic activity increases significantiy in the presence of a thrombus, creating a lytic environment only in that area. It was thought that this characteristic
would lead to fewer systemic bleeding complications because
the t-PA would be active only in the area of a coronary thrombus. However, physiologic clots are present throughout the
body and t-PA creates a generalized lytic state as these clots are
lysed along with the pathologic ones. Because t-PA is a human
product, there is no allergic or antigenic potential. Therefore, it
can be readministered at a later date without risk of antibody
reaction. Therapy with t-PA produces a lower rate of serious
bleeding compared to SK, but the ICB rate is similar (Table 2).
Of all the agents, t-PA is the most potent in terms of arterial patency rates and is not as time-dependent as SK. The efficacy of
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t-PA in terms of restoring patency of the infarct vessel is relatively uniform over at least 8 hours from onset of the symptoms
(36,65,67) (Fig I). SK is far moretime-dependentand the paency rate tends to diminish three hours after occlusion (62).
However, this difference has not resulted in a demonstrable decrease in mortality rate. The dose of t-PA, unlike SK, has been
altered in an attempt to increase the coronary patency. Both
front-loading and weight-dosing t-PA regimens which seem to
increase patency have been proposed and are being used in several studies (47,48). However, at this time the most common
dose of t-PA is 100 mg infused over three hours. The TIMI protocol called for a bolus of 6 to 10 mg followed by an infusion of
50 to 54 mg over the next 60 minutes for a total of 60 mg in the
first hour. The last 40 mg was given in the next two hours at 20
mg/hr (57,74). This regimen does not produce the high ICB rate
seen with the 150 mg dose. Urokinase has been combined with
t-PA, but the two agents did not act synergistically and no increase in patency was seen. Therefore, this combination has not
been used clinically to any extent (81).
Of all thrombolyfic agents, APSAC has the most limited clinical and experimental use. Compared to the vast experience with
SK and the considerable experience with t-PA, only a minimum
of pafients have been studied with APSAC (43,82-85). This
agent is a form of SK. The molecule incorporates an anisoyl site
which must be metabolized before APSAC becomes acfive SK.
It is more clot-specific than SK but not to the degree of t-PA.
APSAC has the longest half-life of all the thrombolyfic agents
(83) (Table 2). Its administrafion does not require an infusion
and can be given simply as a 30 unit bolus over two to five minutes. This property may be important in the prehospital setting
or when establishing several intravenous lines is difficult. As a
derivative of SK, APSAC carries an allergic potenfial. The patient will also develop antibodies which precludes its use at a future date.
The cost of thrombolytic agents is a growing concem, and
there are major differences between the various agents. At
Henry Ford Hospital, charges for the three agents are currently
$ 164 for SK, $2,200 for t-PA, and $1,700 for APSAC (86). With
increasing pressure to control the cost of medical care, this issue
can be a deciding factor in the choice of agent. Moreover, to date
no study has shown definitively that one agent is superior to any
other. The impact of GISSI-2 and lSIS-3 is limited because
these trials varied from the usual heparin protocols used in the
United States. Accordingly, the decision as to which agent to
use should be based on which agent is most readily available in
the emergency department as well as which agent the physician
is most familiar.

Global Utilization of SK and t-PA
for Occluded Coronary Arteries
Future studies may answer the question of the relative advantages of SK, t-PA, or APSAC. Currentiy the Global Utilization
of Streptokinase and rt-PA for Occluded Coronary Arteries
(GUSTO) trial holds such promise. This megatrial will involve
centers in the United States and abroad in a comparison study of
SK, t-PA, and SK combined with t-PA. All patients will receive
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intravenous heparin and aspirin at standard doses. By using the
front-loaded, weight-adjusted, Neuhaus t-PA regimen, GUSTO
will attempt to maximize vessel patency and aggressively test
the "open-artery" theory. In addition, this trial will examine the
question of sustaining early patency by the use of intravenous
heparin and aspirin. An interesting part of this trial will be the
arm which combines SK and t-PA seeking to capitalize on the
early patency power of t-PA with the more sustained lytic effect
of SK. This trial, which is currently in progress, may answer
many of the questions left open by the GISSI-2 and ISlS-3 trials.

Summary
The use of thrombolytic agents allows the emergency physician to attack the primary etiology of an acute MI; occlusion
of a coronary artery by a thrombus. This treatment has had a major impact on mortality and morbidity of acute Ml. However,
thrombolysis has its complications, some of them serious, and
the risks of therapy must be balanced against the benefits. The
complication of greatest concem is ICB which is fatal in the majority of cases. All thrombolytics currentiy in clinical use have
similar ICB rates. While some differences in other complications exist between the thrombolytics, they are too small a factor
to influence the choice of a thrombolytic agent. Currently, only
a minority of acute MI patients are being treated with thrombolytic agents. There are a variety of reasons for this fact, but the
main problem is that patients are excluded by criteria derived
from the experimental trials which established the efficacy
of thrombolytic therapy. Because these studies eliminated the
higher risk patients, the benefits were maximized and the complications minimized. Strict application of the inclusion and exclusion criteria established by such studies is too conservative
and may eliminate many patients who can benefit from thrombolytic therapy. Two such examples are the criteria for age and
time from onset of symptoms. As more trials include older patients, it has become clear that this group can derive considerable benefit from thrombolysis despite a higher rate of complications. The maximum 6-hour time limit from onset of symptoms to initiation of treatment was established by the GISSl-1
trial and has been continued in many other studies. However,
those trials which treated patients outside of this early period do
demonstrate a benefit for late thrombolysis. Although a short interval to treatment is considered the most powerful predictor of
success, reliable as.sessment of this key parameter depends on
the accuracy of the patient's history. Holding to a rigid lime
frame may exclude patients who would otherwise benefit from
treatment. A crucial function of the emergency physician is to
assess all historical factors in order to decide whether an individual patient is a suitable candidate for treatment.
The interpretation of the ECG has great importance because
concrete evidence of myocardial ischemia is necessary before
deciding whether to use a thrombolytic agent. Interpretation of
ECGs which fall outside the classic criteria of I to 2 mm of ST
segment elevation in two consecutive leads becomes difficult in
terms of whether they represent tme myocardial ischemia. In patients with typical chest pain and a LBBB, which may mask
ischemic changes, the use of thrombolytics has shown some
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benefit and is justified. No significant reduction in mortality has
been shown in those patients with chest pain whose ECGs show
only ST segment depression.
To administer thrombolytic therapy successfully, physicians
must be familiar with the three agents currently in use. The use
of front-loaded, weight-adjusted regimens of t-PA is becoming
more popular and its impact on mortality may become more evident as results of new trials, such as GUSTO, are reported.
APSAC may offer an advantage in being able to be given as a
single bolus. SK is the agent which has been in use the longest
and is the least expensive. The choice of agent can be difficult
and unfortunately is clouded by cost issues as well as by medical
ones. The economics of treating MI is a complex issue. Acute
Ml occurs frequently and huge expenses are incurred in its treatment. There are large differences in the cost of the various
agents but thus far no study has clearly shown that any single
agent is superior to any other. Furthermore, no study has clearly
shown that superior patency rates lead to lower mortality rates.
More relevant than pure economic issues, the treating physician
must be familiar with a readily available agent in order to administer it in an efficient manner to the patient presenting to the
emergency department with an acute MI. Despite its difficulties
and regardless of the agents used (APSAC, t-PA, or SK), thrombolytic therapy is the most important intervention in improving
survival in acute MI patients.
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